← All trials
NCT03857165
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 24, 2018
- Primary completion
- Apr 30, 2019
- Completion date
- Jun 20, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanton Pharma Co., Ltd.Lead sponsor
- High Point Clinical Trial CenterOverall official - principal investigator
- Anaheim Clinical TrialsOverall official - principal investigator
- Avail Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.